CLINICAL_TRIALS
research
· 2026-01-21
Clinical Trial Update: Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above [Phase 2]
Summary
Phase 2 clinical trial update evaluating the immunogenicity and safety of SYS6017 in adults aged 40 years and above with herpes zoster.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. | Conditions: Herpes Zoster | Phase 2 | Status: NOT_YET_RECRUITING